REPLY
Cluster Reply, the Reply Group company specialised in Microsoft technology, has provided a digital solution to support health authorities in Bavaria in managing COVID-19 infection chains. The aim is to use digitalised processes to contain, trace and interrupt the chains of infection. This results in concrete time savings for the health authorities and valuable support for the most complete traceability possible.
The solution is aimed at health authorities and enables the digital management and administration of people infected with the virus, as well as possible contact persons. The system captures new corona cases via an easy-to-use interface to check known infection chains and identify new outbreaks. This solution enables health authorities to monitor the situation in real time, analyse the dynamics of case spread and take immediate action to identify and contain individual hotspots at an early stage.
Via a self-service portal, which infected persons can access directly after activation by their public health department, they have the opportunity to report their state of health on a daily basis (symptom diary) and report the history of their contact persons. This helps the authorities to recognise the emergence of potential new chains of infection more quickly and take necessary steps to isolate them.
The solution meets the highest security standards for data processing. It is also possible to individually adapt the infection chain management to the needs of a federal state or a municipality.
°°°
REPLY
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
CLUSTER REPLY
Cluster Reply specializes in delivering Cloud Solutions using the Microsoft Azure platform. Cluster Reply is a global award-winning Microsoft Gold certified partner with over 20 years’ experience delivering application development, integration and cloud infrastructure solutions using Microsoft technology. Delivering a complete cloud Managed Services solution; on-premises, hybrid and cloud to enable you to digitally transform your business with the Microsoft Azure cloud. Cluster Reply have helped our customers to achieve success through offering experience, expertise and best practice guidance on optimizing your current IT investments. www.cluster.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ireland Unveils Seven New Halloween Experiences30.10.2025 15:00:00 CET | Press release
More celebrations than ever across the island of Ireland – the true Home of Halloween With seven brand-new Halloween hubs or experiences launching across the island this month, Ireland has truly become the ultimate destination to celebrate Halloween in 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022209535/en/ Derry Halloween Festival, County Derry~Londonderry Ireland’s Halloween Season Rooted in the ancient Celtic festival of Samhain, Halloween originated in Ireland more than 2,000 years ago and, this year, the island of Ireland is expanding its celebration like never before. With over 340 events planned across the island to celebrate this year, Halloween in Ireland is fast becoming a bucket-list travel experience. Seven new Halloween hubs join existing flagship events across the island of Ireland including the Púca Festival in County Meath and Derry Halloween in Derry-Londonderry which together welcomed over 169
Staloral® Birch Phase III Study Successfully Meets Primary Endpoint, Demonstrating Efficacy in Children and Adolescents30.10.2025 14:56:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis (ARC), with or without asthma, has successfully achieved its primary endpoint. The trial enrolled 553 children aged 5 -17 years with moderate to severe birch pollen-induced ARC, with or without asthma, across 64 sites in 12 European countries and assessed the efficacy and safety of Staloral® birch 300IR daily maintenance dose administered pre-and co-seasonally over two consecutive birch pollen seasons. The YOBI study successfully met its primary endpoint, demonstrating the efficacy of Staloral® Birch in a paediatric population (5-17) with a 41% improvement in the ARC total combined score during the second pollen season compared to placebo. These results were highly statistically significant
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers30.10.2025 14:00:00 CET | Press release
An Alliance to Combat Resistance: Debiopharm and NetTargets will collaborate to develop next-generation, dual-payload Antibody-Drug Conjugates (ADCs) designed to overcome acquired resistance mechanisms in difficult-to-treat cancers. AI-Powered Precision: The collaboration combines NetTargets' proprietary AI discovery platform—to identify synergistic drug pairings—with Debiopharm’s MLINK Duo technology for coordinated delivery of two distinct warheads on a single ADC. Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This allianc
Bending Spoons Raises $710M for Continued Investment and Growth30.10.2025 14:00:00 CET | Press release
Bending Spoons, one of Europe’s leading technology companies, today announced it has raised $710 million in equity at a pre-money valuation of $11 billion. The round was led by accounts advised by T. Rowe Price Investment Management, Inc., with participation from Baillie Gifford, Cox Enterprises, Durable Capital Partners, Fidelity Management & Research Company, Foxhaven Asset Management, and Radcliff, among others. Goldman Sachs International acted as sole placement agent and Clifford Chance served as legal advisor to the transaction. Notarial advisory services were provided by ZNR Notai. “This moment is a validation of a decade’s worth of work and it serves as an important recognition of what we’ve accomplished at Bending Spoons so far. We remain early in our journey and have ambitious plans for continued investment and growth,” shares Luca Ferrari, co-founder and CEO of Bending Spoons. “We’re proud to bring on some of the world’s finest investors who believe in our approach to value
Owlet® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark30.10.2025 13:45:00 CET | Press release
Earning the first-ever SGS Cybersecurity Mark in the baby monitor category, Owlet reinforces its leadership in safety, security, privacy, and innovation. Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that its newest video monitoring device, Dream Sight, is the first and only baby monitor to earn an SGS Cybersecurity Mark, a global certification that recognizes the highest standards in international cybersecurity and privacy. Dream Sight was tested by Brightsight, an SGS company and global leader in cybersecurity evaluations. For parents, this independent recognition provides extra reassurance that Owlet delivers trusted digital solutions backed by strong encryption, secure data management, and advanced privacy safeguards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106669800/en/ Owlet's Dream Sight is the first and only baby monitor to earn an SGS Cybersecu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom